Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Adverse Effects, Drugs Clinical Trials

A listing of Adverse Effects, Drugs medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (21) clinical trials

Post-market Safety Reassessment of Ulinastatin for Injection

In order to find out the application of ulinastatin in real practice clinic , identify the high risk group for adverse event/adverse drug reaction and calculate the adverse event/adverse drug reaction incidence rate, a large sample size clinical trial has been designed. This trial is an observational study. The investigators ...

Phase N/A

National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children

CPNDS will identify ADR predictive markers by comparing DNA and plasma samples from patients that suffer ADRs with samples from control populations that are stratified by medication type and age. The GATC will obtain its clinical material for ADR patients mainly, from hospital-based active surveillance network across Canada's major hospitals. ...

Phase N/A

Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

The purpose of this study is to determine whether genomic effects on antidepressant response differed by class of drug, whether genomic differences between drug responders and nonresponders predict the response of antidepressant and to construct the prediction model for antidepressant treatment in order to aid to select the their genetically ...

Phase N/A

Genetics of QT Prolongation With Antiarrhythmics

Drug-induced long QT syndrome (LQTS), and the subsequent fatal arrhythmia torsade de pointes (TdP), is a major concern with use of a number of medications. Prolongation of the QT interval is the most common cause of withdrawal of medications already on the market, and despite the relatively rarity with non-cardiovascular ...

Phase N/A

Regional Data Exchange to Improve Care for Veterans After Non-VA Hospitalization

Background: Among older VA patients who have Medicare coverage, 43% use both VA and non-VA (Medicare-covered) services. VA and non-VA providers are often uninformed about encounters, treatments and test results provided in the other system. In particular, the absent or delayed notification of a non-VA hospital encounter is a missed ...

Phase N/A

Studying the Performance of OCT C-scan in the Screening for Retinopathy Related to Synthetic Antimalarials

Maculopathy induced by retinal toxicity of synthetic antimalarials is to be screened at the sub-clinical stage. Indeed, when the first visual symptoms appear, macular damage is already irreversible and the clinical picture may even continue to deteriorate for several years after the end of synthetic antimalarial use. In opposition, the ...

Phase N/A

Drug Patch Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs)

The study is about drug patch tests in patients who have history of severe cutaneous drug reaction including Steven Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Drug-induced eosinophilia and systemic symptoms (DRESS), AGEP (Acute generalized exanthematous pustulosis) and generalized bullous fixed drug eruptions. This study also investigate in Enzyme-linked immunosorbent ...

Phase N/A

Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered

The Brigham and Women's Hospital (BWH) Patient Safety Learning Laboratory (PSLL) will develop systems approaches to integrating health information technology (HIT), stakeholder engagement mechanisms, and process design/engineering methods focused on patient safety, development and enhancement of tools, health care system interventions, and translation into practice. The three technological toolkits to ...

Phase N/A

Reducing Post-discharge Adverse Drug Events Amongst the Elderly: a Multi-centre Electronic Deprescribing Intervention

Polypharmacy, or the concomitant use of 5 drugs or more, is a serious health concern and affects more than half of Canadians aged 65 years and older. It is the number one identifiable risk factor for adverse drug events (ADEs), which are responsible for 27,000 hospital admissions annually in Canada ...

Phase N/A

Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity

Drug-induced liver injury (DILI), especially its idiosyncratic for is often an unpredictable complication of drug therapy. Until now it is very challenging to predict occurrence, severity and outcome of DILI. Previous data provide evidence that cells from peripheral blood may reflect hepatocellular damage (Fannin RD, Hepatology. 2010). Own research could ...

Phase N/A